查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1844342

慢性靜脈閉塞治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Chronic Venous Occlusions Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 160 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球慢性靜脈閉塞治療市場價值為 70 億美元，預計到 2034 年將以 4.7% 的複合年成長率成長至 112 億美元。

慢性靜脈閉塞治療市場 - IMG1

靜脈疾病發病率的上升、老齡人口的成長以及治療方法的持續技術進步推動了這一行業的穩步成長。隨著醫療保健系統日益注重改善患者預後，微創療法和個人化治療策略的應用已獲得顯著發展。隨著患者和臨床醫生意識的增強，早期診斷和主動治療計劃正變得越來越普遍。醫療保健宣傳活動、病患教育計畫以及報銷支持範圍的擴大正在推動產業發展。數位醫療技術與傳統護理模式的融合也正在改變治療後管理。價值鏈上的企業，包括設備製造商、藥品開發商和醫療保健提供者，正在建立策略合作夥伴關係，以推出創新解決方案並提高醫療服務的可及性。此外，成熟經濟體不斷成長的醫療支出和政策支持為整個行業的未來成長奠定了堅實的基礎。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 70億美元
預測值 112億美元
複合年成長率 4.7%

慢性靜脈阻塞的治療著重於透過一系列方法（例如壓迫療法、藥物治療、靜脈腔內手術和數位監測工具）來管理長期靜脈阻塞。這些治療方法旨在恢復靜脈血流，預防併發症，減輕症狀，並改善患者的整體生活品質。其潛在病因通常包括血管瘢痕形成、血栓形成和先天性畸形，這些因素會導致需要長期治療的慢性症狀。

2024年，醫療器材市場佔了52.9%的市場佔有率，這歸因於人們對微創治療的日益青睞，以及先進靜脈內器械和壓迫系統的廣泛應用。人們逐漸放棄侵入性手術，這使得恢復更快、風險更低的治療方案越來越受歡迎。消融療法、硬化療法和現代壓迫服等技術的日益普及反映了這一趨勢。患者和醫護人員越來越青睞那些能夠高效治療且對日常生活影響最小的解決方案，這推動了對尖端治療設備的需求。

靜脈曲張領域佔據48.7%的市場佔有率，預計2034年將達到54億美元。這種主導地位主要歸因於靜脈功能不全的高發生率，尤其是在老年人、久坐不動或肥胖人群中。向靜脈內雷射和射頻消融等微創解決方案的轉變正在推動市場擴張。生活方式相關因素和公眾意識的提高正在擴大尋求治療的患者群體，尤其是在40歲及以上的人群中。

2024年，北美慢性靜脈閉塞治療市場佔據40.1%的市場。該地區完善的醫療基礎設施、較高的認知度以及對新療法的早期採用，使其佔據領先地位。老年人口的不斷成長，更容易患上慢性功能不全和血栓等靜脈併發症，這推動了持續的需求。診斷和報銷制度的創新也推動了該地區先進療法的強勁應用。

全球慢性靜脈閉塞治療市場的關鍵參與者包括：輝瑞、波士頓科學公司、泰爾茂、美敦力、Tactile Medical、康樂保、戈爾、拜耳、賽諾菲、Viatris、AngioDynamics、康維特、Sciton、Leucadia Pharmaceuticals (Hikma)、3M、庫克醫療和康維特。慢性靜脈閉塞治療市場的領先公司正優先進行研發，以開發安全性和有效性更高的微創設備和新型藥物。透過策略併購擴大產品組合，使公司能夠整合互補技術並拓寬市場准入。許多公司正在利用與醫院、研究機構和數位健康平台的合作夥伴關係來改善病患監測和長期疾病管理。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 靜脈曲張盛行率不斷上升，同時人們對其治療的認知也不斷提高
      • 微創手術日益受到青睞
      • 骨科手術數量增加
      • 與慢性靜脈功能不全治療療法相關的技術進步
    • 產業陷阱與挑戰
      • 不同治療模式的副作用和風險
      • 嚴格的監管準則
    • 市場機會
      • 門診和行動照護環境的需求不斷成長
      • 數位健康與人工智慧的融合
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 技術格局
    • 當前的技術趨勢
      • 微創支架和導管介入措施的採用率不斷上升
      • 整合先進的影像技術，實現精確的診斷和治療計劃
      • 慢性靜脈功能不全的壓力療法創新發展
    • 新興技術
      • 開發生物可吸收支架以維持長期血管健康
      • 人工智慧驅動的靜脈閉塞治療成像和決策支持
      • 非侵入性超音波療法
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 未來市場趨勢
    • 向門診手術中心護理的強勁轉變
    • 隨著醫療保健服務水準的提高，新興市場的滲透率不斷提高
    • 策略合作推動創新和全球擴張

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 多邊環境協定
  • 競爭定位矩陣
  • 主要市場參與者的競爭分析
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 推出新服務類型
    • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

  • 主要趨勢
  • 裝置
    • 壓縮裝置
    • 硬化療法
    • 靜脈內消融術
      • 雷射燒蝕
      • 射頻消融
    • 靜脈剝離器
    • 其他設備
  • 藥物
    • 止痛藥
    • 抗生素
    • 抗凝血劑
    • 其他藥物

第6章：市場估計與預測：按應用，2021 - 2034

  • 主要趨勢
  • 靜脈曲張
  • 浮腫
  • 深層靜脈栓塞
  • 靜脈淤滯性潰瘍
  • 其他應用

第7章：市場估計與預測：依最終用途，2021 - 2034

  • 主要趨勢
  • 醫院
  • 門診手術中心
  • 其他最終用途

第8章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • 3M
  • AngioDynamics
  • Bayer AG
  • Boston Scientific Corporation
  • Coloplast
  • ConvaTec
  • Cook Medical
  • Gore
  • Leucadia Pharmaceuticals (Hikma)
  • Medtronic
  • Pfizer
  • Sanofi
  • Sciton
  • Tactile Medical
  • Terumo
  • Viatris
簡介目錄
Product Code: 5398

The Global Chronic Venous Occlusions Treatment Market was valued at USD 7 billion in 2024 and is estimated to grow at a CAGR of 4.7% to reach USD 11.2 billion by 2034.

Chronic Venous Occlusions Treatment Market - IMG1

The steady growth is driven by a rising number of venous disorders, growing elderly populations, and continuous technological advancements across treatment approaches. With healthcare systems increasingly focused on improving patient outcomes, the adoption of minimally invasive therapies and personalized treatment strategies has gained significant traction. As awareness grows among both patients and clinicians, early diagnosis and proactive treatment planning are becoming more common. Healthcare campaigns, patient education programs, and expanded reimbursement support are helping propel industry development. The convergence of digital health technologies and traditional care models is also transforming post-treatment management. Companies across the value chain including device makers, pharmaceutical developers, and healthcare providers are forging strategic partnerships to introduce innovative solutions and enhance care accessibility. Additionally, increasing medical expenditure and policy support in mature economies have created a strong foundation for future growth across the sector.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$7 Billion
Forecast Value$11.2 Billion
CAGR4.7%

Chronic venous occlusions treatment focuses on managing long-term venous blockages through a range of approaches like compression therapy, pharmaceuticals, endovenous procedures, and digital monitoring tools. These treatments work to restore venous blood flow, prevent complications, reduce symptoms, and improve overall quality of life for affected patients. The underlying causes often include vascular scarring, thrombosis, and congenital abnormalities, which contribute to chronic symptoms requiring long-term management.

The devices segment held 52.9% share in 2024, attributed to the rising preference for less invasive treatments and broader use of advanced endovenous tools and compression systems. The shift away from invasive surgical options has led to the popularity of procedures with faster recovery and fewer risks. The growing use of techniques such as ablation therapy, sclerotherapy, and modern compression wear reflects this trend. Both patients and healthcare professionals increasingly favor solutions offering efficient outcomes with minimal disruption to daily life, driving demand for cutting-edge treatment devices.

The varicose veins segment held 48.7% share and is expected to reach USD 5.4 billion by 2034. This dominance is largely due to the high incidence of venous insufficiency, especially among older adults and those with sedentary lifestyles or obesity. The shift toward minimally invasive solutions like endovenous laser and radiofrequency ablation is reinforcing market expansion. Lifestyle-related factors and increasing public awareness are expanding the treatment-seeking patient base, particularly among individuals aged 40 and above.

North America Chronic Venous Occlusions Treatment Market held 40.1% share in 2024. The region's well-established healthcare infrastructure, high awareness levels, and early adoption of novel therapies contribute to its leadership position. A growing elderly population, more vulnerable to venous complications such as chronic insufficiency and thrombosis, is fueling continuous demand. Innovations in diagnostics and reimbursement systems have also supported strong uptake of advanced treatments throughout the region.

Key Players involved in the Global Chronic Venous Occlusions Treatment Market: Pfizer, Boston Scientific Corporation, Terumo, Medtronic, Tactile Medical, Coloplast, Gore, Bayer AG, Sanofi, Viatris, AngioDynamics, ConvaTec, Sciton, Leucadia Pharmaceuticals (Hikma), 3M, Cook Medical, and ConvaTec. Leading companies in the chronic venous occlusions treatment market are prioritizing R&D to develop minimally invasive devices and novel pharmaceuticals with enhanced safety and efficacy. Expanding product portfolios through strategic mergers and acquisitions allows firms to integrate complementary technologies and broaden market access. Many are leveraging partnerships with hospitals, research institutions, and digital health platforms to improve patient monitoring and long-term disease management.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of varicose veins coupled with rising awareness regarding its treatment
      • 3.2.1.2 Growing preference for minimally invasive procedures
      • 3.2.1.3 Rise in number of orthopedic procedures
      • 3.2.1.4 Technological advancements pertaining to chronic venous insufficiency treatment therapies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects and risks associated with different treatment modes
      • 3.2.2.2 Strict regulatory guidelines
    • 3.2.3 Market opportunities
      • 3.2.3.1 Growing demand for outpatient and ambulatory care settings
      • 3.2.3.2 Integration of digital health and AI
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
      • 3.5.1.1 Rising adoption of minimally invasive stent and catheter-based interventions
      • 3.5.1.2 Integration of advanced imaging for precise diagnosis and treatment planning
      • 3.5.1.3 Growth in compression therapy innovations for chronic venous insufficiency
    • 3.5.2 Emerging technologies
      • 3.5.2.1 Development of bioresorbable stents for long-term vascular health
      • 3.5.2.2 AI-driven imaging and decision support for venous occlusion treatment
      • 3.5.2.3 Non-invasive ultrasound-based therapies
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
    • 3.9.1 Strong shift toward ambulatory surgical center-based care
    • 3.9.2 Growing penetration in emerging markets with improved healthcare access
    • 3.9.3 Strategic collaborations driving innovation and global expansion

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
    • 4.3.5 Latin America
    • 4.3.6 MEA
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New service type launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Devices
    • 5.2.1 Compression devices
    • 5.2.2 Sclerotherapy
    • 5.2.3 Endovenous ablation
      • 5.2.3.1 Laser ablation
      • 5.2.3.2 Radiofrequency ablation
    • 5.2.4 Vein stripper
    • 5.2.5 Other devices
  • 5.3 Drugs
    • 5.3.1 Analgesics
    • 5.3.2 Antibiotics
    • 5.3.3 Anticoagulants
    • 5.3.4 Other drugs

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Varicose veins
  • 6.3 Edema
  • 6.4 Deep vein thrombosis
  • 6.5 Venous stasis ulcers
  • 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 3M
  • 9.2 AngioDynamics
  • 9.3 Bayer AG
  • 9.4 Boston Scientific Corporation
  • 9.5 Coloplast
  • 9.6 ConvaTec
  • 9.7 Cook Medical
  • 9.8 Gore
  • 9.9 Leucadia Pharmaceuticals (Hikma)
  • 9.10 Medtronic
  • 9.11 Pfizer
  • 9.12 Sanofi
  • 9.13 Sciton
  • 9.14 Tactile Medical
  • 9.15 Terumo
  • 9.16 Viatris